Status:
COMPLETED
Prospective Survey of Menstrual Migraine & Prevention With Eletriptan
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
Pfizer
Conditions:
Migraine
Eligibility:
FEMALE
18-45 years
Phase:
PHASE4
Brief Summary
Women are followed prospectively for 3 months, recording headaches, other symptoms, and menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months.
Detailed Description
Women are followed prospectively for 3 months, recording headaches, other symptoms, and menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months.
Eligibility Criteria
Inclusion
- age 18-45 healthy menstruating female
Exclusion
- cardiac or other conditions precluding use of eletriptan
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT00259649
Start Date
August 1 2004
Last Update
July 4 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15206